Journal of Clinical Oncology, Vol 2, 762-769, Copyright © 1984 by American Society of Clinical Oncology

ARTICLES

Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience

WJ Tester, TJ Kinsella, B Waller, RW Makuch, PA Kelley, E Glatstein and VT DeVita

The medical records of all patients treated for Hodgkin's disease during the years 1964-1981 were reviewed. Four hundred seventy-three previously untreated patients were analyzed. Thirty-four subsequent second malignant neoplasms were observed in 33 patients among those treated for Hodgkin's disease. Eight cases of acute nonlymphocyctic leukemia, one case of chronic myeloid leukemia, three cases of non- Hodgkin's lymphoma, three cases of sarcoma, and 19 other tumors were identified. The ten-year estimated risk of leukemia by treatment was the following: radiotherapy only (0), chemotherapy only (0.02), initial combined radiotherapy-chemotherapy (0.06), and salvage combined radiotherapy-chemotherapy (0.09). The ten-year estimated risk of solid tumors was 0.07 overall, with all treatment groups associated with similar risks. Unlike some other reports, a greater risk of leukemia in patients who began treatment for Hodgkin's disease at age 40 or older was not found. However, a positive association was noted between increasing risk of solid tumors and increasing patient age.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. A. Lichtman Is There an Entity of Chemically Induced BCR-ABL-Positive Chronic Myelogenous Leukemia? Oncologist, June 1, 2008; 13(6): 645 - 654. [Abstract] [Full Text] [PDF]

				A. T. Look Molecular Pathogenesis of MDS Hematology, January 1, 2005; 2005(1): 156 - 160. [Abstract] [Full Text] [PDF]

				F. E. van Leeuwen, W. J. Klokman, M. B. v.’t Veer, A. Hagenbeek, A. D. G. Krol, U. A. O. Vetter, M. Schaapveld, P. van Heerde, J. M. V. Burgers, R. Somers, et al. Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood J. Clin. Oncol., February 1, 2000; 18(3): 487 - 487. [Abstract] [Full Text] [PDF]

				M. A. Smith, L. Rubinstein, J. R. Anderson, D. Arthur, P. J. Catalano, B. Freidlin, R. Heyn, A. Khayat, M. Krailo, V. J. Land, et al. Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins J. Clin. Oncol., February 1, 1999; 17(2): 569 - 569. [Abstract] [Full Text] [PDF]

				A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]

				S. Mach-Pascual, R. D. Legare, D. Lu, M. Kroon, D. Neuberg, R. Tantravahi, R. M. Stone, A. S. Freedman, L. M. Nadler, J. G. Gribben, et al. Predictive Value of Clonality Assays in Patients With Non-Hodgkin's Lymphoma Undergoing Autologous Bone Marrow Transplant: A Single Institution Study Blood, June 15, 1998; 91(12): 4496 - 4503. [Abstract] [Full Text] [PDF]

				E. Joseph, R. Clark, C. Berman, M. Miller, C. Cox, H. Greenberg, and D. S. Reintgen Screening Childhood Cancer Survivors for Breast Cancer Oncologist, August 1, 1997; 2(4): 228 - 234. [Abstract] [Full Text] [PDF]

				P. S. Multani and M. L. Grossbard Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary? Oncologist, February 1, 1996; 1(1): 41 - 55. [Abstract] [Full Text] [PDF]

				J.-P. Riou, S. Ariyan, K. R. Brandow, and L. P. Fielding The Association Between Melanoma, Lymphoma, and Other Primary Neoplasms Arch Surg, October 1, 1995; 130(10): 1056 - 1061. [Abstract] [PDF]

				P. M. Mauch and J. A. Ferry Case 19-1993- A 39-Year-Old Man with Bilateral Renal Masses a Few Months after Treatment for Hodgkin's Disease, Stage IIA N. Engl. J. Med., May 13, 1993; 328(19): 1406 - 1414. [Full Text]

				M. A. Bookman, D. L. Longo, and R. C. Young Late Complications of Curative Treatment in Hodgkin's Disease JAMA, August 5, 1988; 260(5): 680 - 683. [Abstract] [PDF]

				S. L. Hancock, R. T. Hoppe, S. J. Horning, and S. A. Rosenberg Intercurrent Death after Hodgkin Disease Therapy in Radiotherapy and Adjuvant MOPP Trials Ann Intern Med, August 1, 1988; 109(3): 183 - 189. [Abstract] [PDF]

				A. F. LIST, J. P. GREER, J. B. COUSAR, R. S. STEIN, J. M. FLEXNER, F. SINANGIL, J. DAVIS, D. J. VOLSKY, and D. T. PURTILO Non-Hodgkin's Lymphoma After Treatment of Hodgkin's Disease: Association with Epstein-Barr Virus Ann Intern Med, November 1, 1986; 105(5): 668 - 673. [Abstract] [PDF]

				M. H. GREENE, E. L. HARRIS, D. M. GERSHENSON, G. D. MALKASIAN Jr., L. J. MELTON III, A. J. DEMBO, J. M. BENNETT, W. C. MOLONEY, and J. D. BOICE Jr. Melphalan May Be a More Potent Leukemogen than Cyclophosphamide Ann Intern Med, September 1, 1986; 105(3): 360 - 367. [Abstract] [PDF]

				Y. Takaue, M. P. Sullivan, I. Ramirez, K. R. Cleary, and J. van Eys Second Malignant Neoplasm in Treated Hodgkin's Disease: Report of a Patient and Scope of the Problem Arch Pediatr Adolesc Med, January 1, 1986; 140(1): 49 - 51. [Abstract] [PDF]